Product
SHR-1916
1 clinical trial
2 indications
Indication
solid tumorIndication
Protocol SpecificClinical trial
An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumor MalignanciesStatus: Terminated, Estimated PCD: 2022-11-01